AAIC 2025 Abstract
Alzheimer's disease and its severity reduce MEG responses to unexpected auditory stimuli
By Alexandra Krugliak, Mats WJ van Es, Marlou Nadine Perquin, Show 15 more authorsJames Benedict Rowe
Study in peopleBiomarkers
Abstract
Background: Alzheimer's disease (AD) impairs cognition with synaptic and neuronal loss related to amyloid and tau pathology. Drug development needs sensitive and reliable biomarkers for early phase clinical trials. The effects of AD on brain function can be measured by magneto/electroencephalography (M/EEG).
